Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet La... (rcent or greater) were headache nausea d...)

HOME >> MEDICINE >> TECHNOLOGY

Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder

Date:9/24/2009

rcent or greater) were headache, nausea, dizziness and insomnia. Full prescribing information for NUVIGIL is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the S&P 500 Index, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

Cephalon has a growing presence in Europe, the Middle East and Africa. The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology.

The company's proprietary products in the United States include: NUVIGIL, TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV], and ACTIQ(R) (oral transmucosal fentanyl citrate) (C-II). The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at '/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
2. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
3. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
4. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
7. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
8. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Pres. Clinton Announces Commitment From Inter-American Development Bank, Global Network for Neglected Tropical Diseases, and Pan American Health Organization to Mobilize $30 Million to Fight NTDs in the Americas at CGI Conference
11. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS

Post Your Comments:

(Date:12/15/2009)... -- The U.S. Food and Drug Administration (FDA) Endocrinologic ... yes, 4 no, and 1 abstention that AstraZeneca has ... support the use of CRESTOR® (rosuvastatin calcium) in individuals ... or equal to 50 years, women greater than or ... 130 mg/dL; hsCRP greater than or equal to 2.0 ...

(Date:12/15/2009)... MONICA, Calif., Dec. 15 Dakim, Inc. and ... Thanks for Loved Ones, Brain Health Contest, designed to ... symptoms of dementia and Alzheimer,s disease. All five winners ... product designed specifically to help seniors preserve their brain ... kind in senior living communities across the country. ...

(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) today ... announced acquisition of SloMedical S.R.O., a leading ... from tubing sets to complex devices for ... provides a broad set of capabilities to ... Terms of the deal were not disclosed. ...

Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4 Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 2 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3 Flextronics Completes SloMedical Acquisition 2 Medical Heroin Helps Treatment Resistant Addicts 54920 1 Medical Heroin Helps Treatment Resistant Addicts 54920 2 Medical Heroin Helps Treatment Resistant Addicts 54920 3 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 1 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 2 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 3 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 4 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 5 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 6 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 7 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 8 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 9 Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 10 LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 1 LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 2

[0] Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study [0] 5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's [0] Flextronics Completes SloMedical Acquisition

... 6 Four studies highlighting late-breaking research advances in the ... today at the 50th Annual Meeting of the American Society ... , Results from a study examining the ability ... in the inner lining of blood vessels, in patients with ...

... FRANCISCO, Dec. 6 Researchers today report that ... erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of ... who received ESAs needed blood transfusions and utilized ... patients who received ESAs prior to implementation of ...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion

(Date:12/16/2009)... holidays are rapidly approaching and what would be the perfect gift ... cells, of course! Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook ... to look and feel their best! , ... (PRWEB) ... kind of gift does a person get that special woman who ...

(Date:12/15/2009)... have successfully developed a new electrophoretic method for ... blood. The technique, using SARCOSYL-PAGE, has specifically ... the performance characteristics of SDS-PAGE for detecting other ... a grant from the World Anti-Doping Agency (WADA), ... Testing and Analysis published by Wiley-Blackwell. , ...

(Date:12/15/2009)... State Authority, Ban on Annual Benefit Limits, & ... Consumer Watchdog condemned the removal of ... and the public option from the U.S. Senate ... the Senate must still make three essential fixes ... the entire health care system to the insurance ...

(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...

(Date:12/15/2009)... Lady of Lourdes Health Care Services Inc., the parent ... pay the United States $7.95 million to resolve allegations ... today. The two hospitals are Our Lady of Lourdes ... Center of Burlington County (LMC) in Willingboro, N.J. ... by a whistleblower, Tony Kite, in 2005. The lawsuit ...

Breaking Medicine News(10 mins):Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2 Health News:Researchers discover novel method for detecting MIRCERA 2 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4 Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2 Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3 Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2

[0] New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything [1] Researchers discover novel method for detecting MIRCERA [1] The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System [1] Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University [0] Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations

... neurological reward responses , MONDAY, Dec. 3 (HealthDay News) ... brain activity patterns than those who,ve never had the ... at the University of Pittsburgh School of Medicine used ... women who,d recovered from anorexia -- defined as maintaining ...

... are clumps of fiber-like misfolded proteins which many ... , While effective treatment remains an elusive goal, ... chemists suggests a possible new approach. , ... students managed to capture and characterize a crucial ...

... Crawford brings more than 30 years of experience in Public Safety ... ... ESi(R), the global leader in,crisis information management technology, today announced ... Northeast.,Crawford is based in Boston, where he is responsible for ESi ...

... conference to discuss new Medicaid generic prescription drug,reimbursement rule ... use his,power to make sure the legislative fix is ... to be fully implemented in early,2008, will grossly underpay ... Brad Hall, Executive Director of the Kentucky Pharmacists ...

... 3 inVentiv Health, Inc.,(Nasdaq: VTIV ) today ... be held Tuesday, December 11th, 2007 in New York ... 9:00 a.m. as announced earlier, and,will conclude at noon, ... business overview, presentations by the,leaders of each of the ...

... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), developers ... peripheral neuropathy, Molluscum,Contagiosum, and MRSA announces record profits ... ), "Corporate profits increased by 100% over ... disclosure will be released on our annual report,in ...

Other Medicine News:Health News:Brain Activity Points to Origins of Anorexia 2 Health News:UIC chemists characterize Alzheimer's neurotoxin structure 2 Health News:ESi Announces Strategic New Hire in Boston 2 Health News:Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule 2 Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 2 Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 3 Health News:ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October 2

Brain Activity Points to Origins of Anorexia UIC chemists characterize Alzheimer's neurotoxin structure ESi Announces Strategic New Hire in Boston Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule inVentiv Health Provides Updated Information on December 11th Investor Day ReBuilder Medical Technologies, Inc. Reports Doubled Profits for October

Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....

Two opposing 62 mirrors provide a complete view of the anterior chamber angle with only a 180 lens rotation. Methylcellulose and no methylcellulose designs available....

Lacrimal cannula blunt tip with 0.3 mm side port, straight....

McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....

Medicine Products:

Ocular Thorpe Four Mirror Gonio Ocular Two Mirror Gonio Mcintyre Cannula McIntyre Lacrimal Cannula

Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet La...(rcent or greater) were headache nausea d...),Health